Natural Capsules Approves ₹10 Crore Promoter Share And Warrant Issue

Q1 FY27 Consolidated Results YoY: Revenue at 48.7 Cr vs 43.2 Cr, up 12.7%. EBITDA at 3.5 Cr vs 0.7 Cr, up 412.3%. EBITDA Margin at 7.1% vs 1.6%, expansion of 550bps; Other Income rose to 2.4 Cr vs 0.4 Cr. PAT loss widened to 5.7 Cr vs loss of 5.6 Cr. API revenue increased to 5.7 Cr from 1.0 Cr, but API loss widened to 8.0 Cr from 7.0 Cr, while capsule revenue declined 2.8% and segment profit rose 46.9%. Board approved a promoter preferential issue comprising 2 Cr of equity shares and 8 Cr of convertible warrants at ₹160 per security, subject to shareholder approval; full warrant conversion would raise promoter holding to 11.12%.